Patents by Inventor Nishith Chaturvedi
Nishith Chaturvedi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873328Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 1, 2022Date of Patent: January 16, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11866477Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 12, 2022Date of Patent: January 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220402991Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: August 1, 2022Publication date: December 22, 2022Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220402992Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: August 12, 2022Publication date: December 22, 2022Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11485766Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: December 28, 2020Date of Patent: November 1, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11447535Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: April 5, 2019Date of Patent: September 20, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11242373Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 4, 2020Date of Patent: February 8, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20210206823Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: December 28, 2020Publication date: July 8, 2021Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11046744Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 4, 2020Date of Patent: June 29, 2021Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20200362007Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: August 4, 2020Publication date: November 19, 2020Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20190309040Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: ApplicationFiled: April 5, 2019Publication date: October 10, 2019Inventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20080108646Abstract: The present invention relates to optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.Type: ApplicationFiled: July 23, 2007Publication date: May 8, 2008Inventors: Mahesh Patel, Shivkumar Agarwal, Sreenivas Kandepu, Nitin Shetty, Dilip Upadhyay, Nishith Chaturvedi, Abraham Thomas, Noel De Souza, Habil Khorakiwala
-
Patent number: 6750224Abstract: The present invention relates to optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(−)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.Type: GrantFiled: August 17, 2000Date of Patent: June 15, 2004Assignee: Wockhardt LimitedInventors: Mahesh Vithalbhai Patel, Shivkumar Agarwal, Sreenivas Kandepu, Nitin Shetty, Dilip Upadhyay, Nishith Chaturvedi, Abraham Thomas, Noel John De Souza, Habil Fakhruddin Khorakiwala
-
Patent number: 4908404Abstract: A water soluble cationic peptide-containing graft copolymer exhibiting a number average molecular weight of from about 30,000 to about 500,000 are provided comprising:(a) a polymeric backbone containing or capable of modification to include free primary or secondary amine functional groups for reaction with an amino acid or peptide graft and exhibiting a number average molecular weight from about 10,000 to about 250,000; and(b) an amino acid or peptide graft reacted with from at least about 5% to about 100% of the primary or secondary amine functional groups of the polymeric backbone, wherein said amino acid or peptide graft comprises at least one 3,4-dihydroxyphenylalaine (Dopa) amino acid or a precursor thereof capable of hydroxylation to the Dopa form.Type: GrantFiled: August 22, 1988Date of Patent: March 13, 1990Assignee: BioPolymers, Inc.Inventors: Christine V. Benedict, Nishith Chaturvedi